Pfizer 2014 Annual Report Download - page 59

Download and view the complete annual report

Please find page 59 of the 2014 Pfizer annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 75

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75

PFIZER ANNUAL REVIEW 2014 www.pzer.com/annual 59
ANNUAL REVIEW 2014
Our World > Access to Medicines
ACCESS TO MEDICINES
Helping Women Plan Their Families —
Expanded Access to Sayana® Press
Long-acting Contraceptive
A novel agreement with the Bill & Melinda Gates Foundation and
the Children’s Investment Fund Foundation will help expand access
to Pzer’s long-acting contraceptive, Sayana® Press, for millions of
women most in need in 69 of the world’s poorest countries.
Sayana Press, a pre-lled, single-use, non-reusable injection,
is a re-designed version of an injectable contraceptive from
Pzer’s Global Established Pharma’s (GEP) women’s health
portfolio. Created with the target population of women in mind, it
eliminates the need to prepare a needle and syringe, allowing the
contraceptive to be administered by health workers at home or in
other non-medical settings.
Through this agreement and the support of a public/private sector
consortium including PATH, the United Kingdom’s Department for
International Development, the United Nations Population Fund,
and the United States Agency for International Development,
Sayana Press will be sold for one U.S. dollar per dose to qualied
purchasers, who can help enable the poorest women in these
countries to have access to the contraceptive at reduced or no cost.
This novel collaboration expands access to the contraceptive,
Sayana® Press, in 69 of the world’s poorest countries.
Sayana® Press (medroxyprogesterone acetate) is not approved or
available for use in the United States. (Photo: PATH)
Experts have identied the need for a contraceptive method
that can be administered in low resource, non-clinic settings.
Sayana® Press (medroxyprogesterone acetate) is not approved or
available for use in the United States. (Photo: PATH)
Q: HOW DOES PFIZER MAKE SURE
PEOPLE AROUND THE WORLD CAN
AFFORD OUR MEDICINES?
INDRANIL BAGCHI
GLOBAL HEALTH & VALUE
Q: WHAT PROGRAMS DOES PFIZER HAVE
TO HELP PEOPLE ACCESS OUR MEDICINES
GLOBALLY?
CAROLINE ROAN
CORPORATE RESPONSIBILITY